

Urethral Stricture Treatment Devices - Market Insights, Competitive Landscape and Market Forecast-2027

Medical Market (7-10 Business Days) | 2022-07-01 | 100 pages | DelveInsight

AVAILABLE LICENSES:

- Single User Price \$2750.00
- Site License Price \$5500.00
- Enterprise Price \$8250.00

Report description:

Urethral Stricture Treatment Devices Market By Product Type (Urethral Dilators, Urethral Stents, Urethral Balloon Dilation Catheters, And Urinary Catheters), By Stricture Location (Anterior And Posterior), By End User (Hospitals, Specialty Clinics, And Others), and by geography is expected to grow at a steady CAGR (forecast period- 2022-2027) owing to increase in probability of urethral stricture formation as a complication of cancer treatment for prostate and colorectal cancers as well as extensive use of urinary catheters

Global urethral stricture treatment devices market was valued at USD 1.48 billion in 2020, growing at a CAGR of 7.10% during the forecast period from 2022 to 2027 to reach USD 2.23 billion by 2027. The demand for urethral stricture treatment devices is witnessing a surge majorly due to the rising prevalence of cancers in the pelvic region such as colorectal and prostate cancers wherein the cancer treatment is linked with increased probability of urethral stricture formation, growing prevalence of benign prostatic hyperplasia in which urethral stricture may form as a complication of surgical interventions, increasing geriatric population wherein aging plays a major role in the development of numerous diseases such as neurogenic bladder leading to the development of urethral strictures due to extensive use of urinary catheters, and advancements in product development such as drug-eluting urology balloon thereby boosting the growth of the urethral stricture treatment devices market during the forecast period.

Urethral Stricture Treatment Devices Market Dynamics:

The urethral stricture treatment devices market is observing a surge in product demand due to plethora of reasons with one of them being the rising prevalence of various cancers specifically in the pelvic region such as colorectal and prostate cancers. As per the data cited by the World Health Organization (WHO), in 2020, cancer of the colon and rectum were the third-most common cancer type globally and accounted for 1.93 million new cases. In the same factsheet by the WHO, in 2020, prostate cancer was

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

the fourth-most prevalent cancer type globally and accounted for 1.41 million new cases. Urethral strictures have been associated as a complication of radiation treatment for prostate and rectal cancers, surgery for an enlarged prostate or prostate cancer, or trauma to the genitals or perineum. It has been established in various studies that radiation therapy for cancer treatment, particularly prostate cancer, leads to reduced vascularity around the treatment area. Furthermore, the risk for developing urethral strictures appear to enhance further in patient receiving both the brachytherapy and external beam radiation therapy. Additionally, it has also been reported that radical prostatectomy also significantly increases the chances of the formation of urethral strictures thereby indicating that treatment of cancers in the pelvic region may result in the formation of urethral strictures. Therefore, the rising prevalence of cancers in the pelvic region may result in the increased incidence of urethral strictures which in turn may drive the demand for urethral strictures treatment devices ultimately driving the urethral strictures treatment devices market during the forecast period.

Another important aspect driving the demand for urethral stricture treatment devices market is the rising geriatric population. As per the statistics quoted by the World Health Organization in their Decade of Healthy Ageing (2020-2030) Report, it has been estimated that people in the age bracket of 60 years and older will account for 34% more share in the total population, increasing from one billion in 2019 to 1.4 billion by 2030. The report further mentioned that by 2050, the global elderly population is expected to reach 2.1 billion. Aging is considered as one of the key risk factors that heavily contributes in the development of various indications such as benign prostatic hyperplasia (BPH), neurogenic bladder among other indications. BPH is most commonly treated by simple prostatectomies and transurethral resection of the prostate wherein urethral strictures are reported as a common complication. Furthermore, the increasing prevalence of neurogenic bladder also results in the increased chances of urethral stricture formation due to trauma or injury caused with the extensive use of urinary catheters. Therefore, the rising geriatric population is expected to result in increasing prevalence of diseases such as BPH where the treatment may result in the formation of urethral strictures, thereby bolstering the growth of the urethral stricture treatment devices in coming years.

However, device-related complications and the availability of alternative surgical approaches such as urethroplasty may be limiting factors for the growth of the urethral stricture treatment devices market.

Besides the above-mentioned factors, the urethral stricture treatment devices market registered a period of decline in revenue generation due to the COVID-19 pandemic. The lockdown implemented by various governments worldwide to contain the spread of the COVID-19 infection resulted in postponement of outpatient consultations and various surgeries across all medical specialties specifically impacting elective procedures. This led to a considerable reduction in the demand for urethral stricture treatment procedures were classified under non-emergency procedures. Furthermore, the implementation of global lockdown in also impacted the procurement and supply chain. Although, the regulatory approval of various COVID-19 vaccines and mass vaccination programs have been crucial in reestablishing the demand for urethral stricture treatment devices, thereby presenting a positive growth environment for the urethral stricture treatment devices market during the forecast period.

Urethral Stricture Treatment Devices Market Segment Analysis:

Urethral Stricture Treatment Devices Market by Product Type (Urethral Dilators, Urethral Stents, Urethral Balloon Dilation Catheters, and Urinary Catheters), by Stricture Location (Anterior and Posterior), by End User (Hospitals, Specialty Clinics, and Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World).

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

In the product segment of the urethral stricture treatment devices market, the urethral balloon dilation catheters category is expected to register a healthy CAGR in the urethral stricture treatment devices market during the forecast period. This can be attributed to the advantages offered by these devices over their counterparts. Balloon dilation is a well-tolerated, safe, office-based procedure that offers multiple advantages over sequential rigid dilation and internal urethrotomy. It is associated with minimal complications. Furthermore, urethral balloon dilation is considered as a minimally invasive technique that has the potential advantage of being less morbid and is technically less challenging to perform. It is also considered to be less traumatic than sequential rigid dilatation.

Owing to the advantages associated with the urethral balloon dilation catheters, there have been an increase in the development of newer products aimed at treating urethral strictures. For instance, in December 2021, Urotronic received the regulatory approval from the US Food and Drug Administration for their product- Optilume, drug-coated urology balloon, which elutes a highly lipophilic drug, paclitaxel that limits hyperactive cell proliferation and the fibrotic scar tissue generation that results in stricture recurrence.

Therefore, the advantages associated with urethral balloon dilation and the innovation in product development are expected to boost the demand for this product category thereby ultimately propelling the market for urethral balloon dilation catheters during the forecast period.

North America is expected to dominate the overall Urethral Stricture Treatment Devices Market:

Among all the regions, North America is estimated to account for the largest share in the urethral stricture treatment devices market. This domination is due to the increase in prevalence of sexually transmitted diseases, increasing prevalence of cancers in the region. Furthermore, the rising geriatric population as well as growing cases of obesity in the US population are also expected to result in growing number of urethral strictures in the North American region. Additionally, extensive research and development activities pertaining to product development and conducive regulatory environment further helps product manufacturers to generate more revenue from the region.

One of the key driving factors of the United States urethral stricture treatment devices market is the interplay of various factors in the country. For instance, as per the data cited by the Centers for Disease Control and Prevention (2021), in 2019, 2.6 million cases of sexually transmitted diseases were reported in the country registering a 6th-consecutive year increase from 1.4 million in 2014. STDs like gonorrhea are reported to cause infection and inflammation in the urethra, leading to scarring and stricture. Some chronic inflammatory skin conditions like lichen sclerosus can also cause urethral strictures. Therefore, the presence of large patient population suffering from sexually transmitted diseases correlates to the presence of a potential patient population that may resort to using urethral stricture devices as a treatment method, thus driving the product demand in the nation.

Moreover, increasing obese population is also expected to drive the demand for urethral stricture treatment devices in the country. For instance, as per the data provided by the CDC (2021), in 2017-2018, the obesity prevalence in the country was 42.4%. Obesity has been associated with increased mean urethral stricture length in obese patients compared to patients with a normal body-mass index.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Thus, the interplay of all the aforementioned factors are likely to fuel the market growth of urethral stricture treatment devices in the United States during the forecast period.

Urethral Stricture Treatment Devices Market Key Players:

Some of the key market players operating in the urethral stricture treatment devices market includes Boston Scientific Corporation, Laborie, Cook, Teleflex Incorporated, B. Braun Melsungen AG, Allium Ltd., Pnn Medical A/S, Zhejiang ChuangXiang Medical Technology co., LTH, UROMED Kurt Drews KG, Med pro Medical B.V., BD, Cardinal Health. Coloplast, ConvaTec Inc, BACTIGUARD AB and others.

Recent Developmental Activities in Urethral Stricture Treatment Devices Market:

? In December 2021, Urotronic received the regulatory approval from the US Food and Drug Administration for their product- Optilume, drug-coated urology balloon, which elutes a highly lipophilic drug, paclitaxel that limits hyperactive cell proliferation and the fibrotic scar tissue generation that results in stricture recurrence.

Key Takeaways from the Urethral Stricture Treatment Devices Market Report Study

? Market size analysis for current urethral stricture treatment devices market size (2021), and market forecast for 5 years (2022-2027)

? The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the urethral stricture treatment devices market.

? Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years

? Key companies dominating the global urethral stricture treatment devices market.

? Various opportunities available for the other competitor in the urethral stricture treatment devices market space.

? What are the top performing segments in 2021? How these segments will perform in 2027.

? Which is the top-performing regions and countries in the current urethral stricture treatment devices market scenario?

? Which are the regions and countries where companies should have concentrated on opportunities for urethral stricture treatment devices market growth in the coming future?

Target Audience who can be benefited from this Urethral Stricture Treatment Devices Market Report Study

? Urethral stricture treatment devices products providers

? Research organizations and consulting companies

? Urethral stricture treatment device-related organizations, associations, forums, and other alliances

? Government and corporate offices

? Start-up companies, venture capitalists, and private equity firms

? Distributors and Traders dealing in urethral stricture treatment devices

? Various End-users who want to know more about the urethral stricture treatment devices market and latest technological developments in the urethral stricture treatment devices market.

Frequently Asked Questions for Urethral Stricture Treatment Devices Market:

1. What is a Urethral Stricture Treatment Device?

A urethral stricture treatment device is a medical device which helps in treating the narrowing of the urethra by opening it up and helping in passage of urine. Urethral dilators, urology balloons, and urethral stents among other interventions.

2. What is the market for Global Urethral Stricture Treatment Devices?

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global urethral stricture treatment devices market was valued at USD 1.48 billion in 2020, growing at a CAGR of 7.10% during the forecast period from 2022 to 2027 to reach USD 2.23 billion by 2027.

3. What are the drivers for Global Urethral Stricture Treatment Devices Market?

The demand for urethral stricture treatment devices is witnessing a surge majorly due to the rising prevalence of cancers in the pelvic region such as colorectal and prostate cancers wherein the cancer treatment is linked with increased probability of urethral stricture formation, growing prevalence of benign prostatic hyperplasia in which urethral stricture may form as a complication of surgical interventions, increasing geriatric population wherein aging plays a major role in the development of numerous diseases such as neurogenic bladder leading to the development of urethral strictures due to extensive use of urinary catheters, and advancements in product development such as drug-eluting urology balloon thereby boosting the growth of the urethral stricture treatment devices market during the forecast period.

4. Who are the key players operating in Global Urethral Stricture Treatment Devices Market?

Some of the key market players operating in the urethral stricture treatment devices market includes Boston Scientific Corporation, Laborie, Cook, Teleflex Incorporated, B. Braun Melsungen AG, Allium Ltd., Pnn Medical A/S, Zhejiang ChuangXiang Medical Technology co., LTH, UROMED Kurt Dews KG, Med pro Medical B.V., BD, Cardinal Health. Coloplast, ConvaTec Inc, BACTIGUARD AB and others.

5. Which region has the highest share in Urethral Stricture Treatment Devices market?

Among all the regions, North America is estimated to account for the largest share in the urethral stricture treatment devices market. This domination is due to the increase in prevalence of sexually transmitted diseases, increasing prevalence of cancers in the region. Furthermore, the rising geriatric population as well as growing cases of obesity in the US population are also expected to result in growing number of urethral strictures in the North American region. Additionally, extensive research and development activities pertaining to product development and conducive regulatory environment further helps product manufacturers to generate more revenue from the region.

Table of Contents:

- 1. Urethral Stricture Treatment Devices Market Report Introduction
- 2. Urethral Stricture Treatment Devices Market Executive Summary
 - 2.1. Scope of the Study
 - 2.2. Market at Glance
 - 2.3. Competitive Assessment
 - 2.4. Financial Benchmarking
- 3. Regulatory Analysis
 - 3.1. The United States
 - 3.2. Europe
 - 3.3. Japan
 - 3.4. China

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

4. Urethral Stricture Treatment Devices Market Key Factors Analysis
 - 4.1. Urethral Stricture Treatment Devices Market Drivers
 - 4.1.1. Rising Prevalence of Cancers in the Pelvic Region
 - 4.1.2. Increasing Cases of Benign Prostatic Hyperplasia
 - 4.1.3. Growing Geriatric Population Base
 - 4.1.4. Technological Advancements in Product Development
 - 4.2. Urethral Stricture Treatment Devices Market Restraints and Challenges
 - 4.2.1. Device-Related Complications
 - 4.2.2. Availability of Alternative Surgical Approaches such as Urethroplasty
 - 4.3. Urethral Stricture Treatment Devices Market Opportunities
 - 4.3.1. Improving on the Product Design
 - 4.3.2. Targeting Emerging Markets for Product Launches
5. Urethral Stricture Treatment Devices Market Porter's Five Forces Analysis
 - 5.1. Bargaining Power of Suppliers
 - 5.2. Bargaining Power of Consumers
 - 5.3. Threat of New Entrants
 - 5.4. Threat of Substitutes
 - 5.5. Competitive Rivalry
6. COVID-19 Impact Analysis on Urethral Stricture Treatment Devices Market
7. Urethral Stricture Treatment Devices Market Layout
 - 7.1. By Product Type
 - 7.1.1. Urethral Dilators
 - 7.1.2. Urethral Stents
 - 7.1.3. Urethral Balloon Dilation Catheters
 - 7.1.4. Urinary Catheters
 - 7.2. By Stricture Location
 - 7.2.1. Anterior
 - 7.2.2. Posterior
 - 7.3. By End User
 - 7.3.1. Hospitals
 - 7.3.2. Specialty Clinics
 - 7.3.3. Others
 - 7.4. By Geography
 - 7.4.1. North America
 - 7.4.1.1. North America Urethral Stricture Treatment Devices Market, by Country
 - 7.4.1.4.1. United States
 - 7.4.1.4.2. Canada
 - 7.4.1.4.3. Mexico
 - 7.4.2. Europe
 - 7.4.2.1. Europe Urethral Stricture Treatment Devices Market, by Country
 - 7.4.2.4.1. France
 - 7.4.2.4.2. Germany
 - 7.4.2.4.3. United Kingdom
 - 7.4.2.4.4. Italy
 - 7.4.2.4.5. Spain
 - 7.4.2.2.6. Russia
 - 7.4.2.2.7. Rest of Europe

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.4.3. Asia-Pacific
 - 7.4.3.1. Asia-Pacific Urethral Stricture Treatment Devices Market, by Country
 - 7.4.3.4.1. China
 - 7.4.3.4.2. Japan
 - 7.4.3.4.3. India
 - 7.4.3.4.4. Australia
 - 7.4.3.4.5. South Korea
 - 7.4.3.4.6. Rest of Asia Pacific
 - 7.4.4. Rest of the World (RoW)
 - 7.4.4.1. RoW Urethral Stricture Treatment Devices Market, by Region
 - 7.4.4.4.1. Middle East
 - 7.4.4.4.2. Africa
 - 7.4.4.4.3. South America
- 8. Urethral Stricture Treatment Devices Market Company and Product Profiles
 - 8.1. Boston Scientific Corporation
 - 8.1.1. Company Overview
 - 8.1.2. Company Snapshot
 - 8.1.3. Financial Overview
 - 8.1.4. Product Listing
 - 8.1.5. Entropy
 - 8.2. Laborie
 - 8.2.1. Company Overview
 - 8.2.2. Company Snapshot
 - 8.2.3. Financial Overview
 - 8.2.4. Product Listing
 - 8.2.5. Entropy
 - 8.3. Cook
 - 8.3.1. Company Overview
 - 8.3.2. Company Snapshot
 - 8.3.3. Financial Overview
 - 8.3.4. Product Listing
 - 8.3.5. Entropy
 - 8.4. Teleflex Incorporated
 - 8.4.1. Company Overview
 - 8.4.2. Company Snapshot
 - 8.4.3. Financial Overview
 - 8.4.4. Product Listing
 - 8.4.5. Entropy
 - 8.5. B. Braun Melsungen AG
 - 8.5.1. Company Overview
 - 8.5.2. Company Snapshot
 - 8.5.3. Financial Overview
 - 8.5.4. Product Listing
 - 8.5.5. Entropy
 - 8.6. Allium Ltd
 - 8.6.1. Company Overview
 - 8.6.2. Company Snapshot

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.6.3. Financial Overview
- 8.6.4. Product Listing
- 8.6.5. Entropy
- 8.7. Pnn Medical A/S
- 8.7.1. Company Overview
- 8.7.2. Company Snapshot
- 8.7.3. Financial Overview
- 8.7.4. Product Listing
- 8.7.5. Entropy
- 8.8. Zhejiang ChuangXiang Medical Technology co., LTH
- 8.8.1. Company Overview
- 8.8.2. Company Snapshot
- 8.8.3. Financial Overview
- 8.8.4. Product Listing
- 8.8.5. Entropy
- 8.9. UROMED Kurt Drews KG
- 8.9.1. Company Overview
- 8.9.2. Company Snapshot
- 8.9.3. Financial Overview
- 8.9.4. Product Listing
- 8.9.5. Entropy
- 8.10. Med pro Medical B.V.
- 8.10.1. Company Overview
- 8.10.2. Company Snapshot
- 8.10.3. Financial Overview
- 8.10.4. Product Listing
- 8.10.5. Entropy
- 8.11. BD
- 8.11.1. Company Overview
- 8.11.2. Company Snapshot
- 8.11.3. Financial Overview
- 8.11.4. Product Listing
- 8.11.5. Entropy
- 8.12. Coloplast
- 8.12.1. Company Overview
- 8.12.2. Company Snapshot
- 8.12.3. Financial Overview
- 8.12.4. Product Listing
- 8.12.5. Entropy
- 8.13. Med pro Medical B.V.
- 8.13.1. Company Overview
- 8.13.2. Company Snapshot
- 8.13.3. Financial Overview
- 8.13.4. Product Listing
- 8.13.5. Entropy
- 8.14. ConvaTec Inc
- 8.14.1. Company Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.14.2. Company Snapshot
- 8.14.3. Financial Overview
- 8.14.4. Product Listing
- 8.14.5. Entropy
- 8.15. BACTIGUARD AB
- 8.15.1. Company Overview
- 8.15.2. Company Snapshot
- 8.15.3. Financial Overview
- 8.15.4. Product Listing
- 8.15.5. Entropy
- 9. KOL Views
- 10. Project Approach
- 11. About DelveInsight
- 12. Disclaimer & Contact Us

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Urethral Stricture Treatment Devices - Market Insights, Competitive Landscape and Market Forecast-2027

Medical Market (7-10 Business Days) | 2022-07-01 | 100 pages | DelveInsight

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$2750.00
	Site License Price	\$5500.00
	Enterprise Price	\$8250.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-14"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com
www.scotts-international.com